13 August 2018
Visiongain has launched a new pharma report Global Medical Marijuana Market 2017-2027: Chronic Pain, Arthritis, Migraine, Cancer, National Markets, Patent Analysis, Leading Companies
Scientific studies of the extract of marijuana, called cannabinoids, have led to two FDA-approved medications that contain cannabinoid chemicals in pill form. Currently, the two main extract from the marijuana plant that are being used for medical treatments are THC and CBD. THC increases appetite and reduces nausea. THC also decrease pain, inflammation, and muscle control problems. CBD is useful in reducing pain and inflammation, controlling epileptic seizures, muscle spasms caused by multiple sclerosis, nausea, poor appetite, weight loss, crohn’s diseases and possibly treating mental illness and addictions.
The lead analyst of the report commented “Medical Marijuana is one the most promising method to treat various kinds of cancer. Moreover, scientists are doing constant research to make medical marijuana more effective. Hence, increasing research in the improvement of medical marijuana and constant development to find new treatment of cancer is one of the main factors driving the growth of this market.
The growing number of states legalizing medical marijuana and increasing demand for cannabis in medical applications are some of the pivotal factors that are expected to propel the demand for medical marijuana over the coming years.”
Leading companies featured in the report include Cara Therapeutics, Inc., Cannabis Sativa, Inc., CannaGrow Holdings, Inc., Aphios Corporation, United Cannabis Corporation, Growblox Sciences, Inc., GreenGro Technologies, Inc., GW Pharmaceutical, PLC., International Consolidated Companies, Inc., Lexaria Biosciences Corp.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.